Biolidics has a wide range of applications for cancer diagnosis, prognosis, treatment selection, and treatment monitoring, and its operations are spread across Singapore, Japan, China, Europe, the United States, Hong Kong, the Philippines, Indonesia, and others. The company derives major revenue from the infectious diseases segment, which involves identifying and assessing potential collaboration partners, technology, products and services, product development, innovation and improvement, and the management of a global distributorship network and direct customers in the infectious diseases field.